Nimbolide, a major limonoid constituent of Azadirachta
indica, commonly known as neem, has attracted increasing
research attention owing to its wide spectrum of pharmacological properties,
predominantly anticancer activity. Nimbolide is reported to exert
potent antiproliferative effects on a myriad cancer cell lines and
chemotherapeutic efficacy in preclinical animal tumor models. The
potentiality of nimbolide to circumvent multidrug resistance and aid
in targeted protein degradation broaden its utility in enhancing therapeutic
modalities and outcome. Accumulating evidence indicates that nimbolide
prevents the acquisition of cancer hallmarks such as sustained proliferation,
apoptosis evasion, invasion, angiogenesis, metastasis, and inflammation
by modulating kinase-driven oncogenic signaling networks. Nimbolide
has been demonstrated to abrogate aberrant activation of cellular
signaling by influencing the subcellular localization of transcription
factors and phosphorylation of kinases in addition to influencing
the epigenome. Nimbolide, with its ever-expanding repertoire of molecular
targets, is a valuable addition to the anticancer drug arsenal.